Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

A global phase 3 study evaluated the pharmacokinetics, efficacy, and safety of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in 63 previously treated male patients (12-61 years) with severe hemophilia B (factor IX [FIX] activity ≤2%). The study included 2 groups: gro...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Santagostino, Elena, Martinowitz, Uri, Lissitchkov, Toshko, Pan-Petesch, Brigitte, Hanabusa, Hideji, Oldenburg, Johannes, Boggio, Lisa, Negrier, Claude, Pabinger, Ingrid, von Depka Prondzinski, Mario, Altisent, Carmen, Castaman, Giancarlo, Yamamoto, Koji, Álvarez-Roman, Maria-Teresa, Voigt, Christine, Blackman, Nicole, Jacobs, Iris
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2016
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4825413/
https://ncbi.nlm.nih.gov/pubmed/26755710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-09-669234
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia